Clinical trials
Colorectal Cancer Recurrent clinical trials
Below are recruiting colorectal cancer recurrent clinical trials, each written for real people, not researchers. We’re tracking 230 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05740956RecruitingPhase 1
Drug study for cancers with HRR gene or HRD changes
This Phase 1 study tests HS-10502 in people with advanced solid tumors that have certain DNA repair problems (HRR or HRD). It may help by finding a safe dose and seeing whether the drug can shrink tumors in cancers that have specific genetic features.
Beijing, Beijing MunicipalityAges 18–75 - NCT05797467RecruitingPhase 3
After-surgery chemo plus targeted therapy for colon cancer
This Phase 3 trial studies whether adding targeted therapy to standard chemotherapy after surgery helps people with stage T3-4, N2 colon cancer live longer or have fewer cancer returns. You would be assigned to receive chemotherapy with targeted therapy or chemotherapy alone, based on the study plan.
Guangzhou, GuangdongAges 18–75 - NCT05959356RecruitingPhase 2
First-line treatment for left-sided metastatic colon cancer with specific tumor markers
This Phase 2 trial tests a combination of medicines (cetuximab, envafolimab, and chemotherapy) as the first treatment for certain left-sided metastatic colorectal cancers. It may help by slowing or shrinking the cancer in people whose tumor has no RAS/BRAF mutations and is microsatellite-stable (MSS).
Foshan, GuangdongAges 18 years+ - NCT06118762RecruitingPhase 4
Study of fruquintinib plus raltitrexed for advanced colorectal cancer
This trial tests two drugs, fruquintinib and raltitrexed, for people with metastatic colorectal cancer that has stopped responding to or is no longer tolerable after standard treatments like fluorouracil, oxaliplatin, and irinotecan. The goal is to see if this combination can help shrink or control the cancer.
Nanchang, JiangxiAges 18 years+ - NCT06148402RecruitingPhase 2
A new combination therapy for advanced colorectal cancer
This trial tests a new combination of three drugs (fruquintinib, camrelizumab, and capecitabine) for people with colorectal cancer that has spread or cannot be removed and has stopped responding to a standard first chemotherapy. It is for those whose cancer progressed after a specific first treatment called FOLFOXIRI.
Guangzhou, GuangdongAges 18 years+ - NCT06193356Recruiting
Can endoscopists learn to spot scar after polyp removal?
This study tests whether endoscopists can learn to see scarring and find any remaining tissue after polyp removal. It may help improve how doctors check for cancer coming back.
GhentAges 18 years+ - NCT06242067RecruitingPhase 2
Second-line treatment for advanced colorectal cancer
This trial tests a new treatment for people with advanced colorectal cancer that has spread or come back after initial chemotherapy. It is for those who have already received standard first-line therapy and are now looking for a second treatment option.
Jinan, ShandongAges 18–75 - NCT06243393RecruitingPhase 2/Phase 3
Sacituzumab govitecan for advanced colorectal cancer
This study tests a drug called sacituzumab govitecan for people with metastatic colorectal cancer who have already tried several standard treatments. It may be an option if your cancer is not MSI-H or dMMR and you haven't had irinotecan recently.
Heidelberg, Baden-WurttembergAges 18 years+ - NCT06259149Recruiting
Timing of blood clot prevention after colorectal cancer surgery
This study looks at when to start blood thinners after surgery for colorectal cancer. The goal is to find the safest time to prevent blood clots without increasing bleeding risk.
Shanghai, Shanghai MunicipalityAges 18–110 - NCT06349642Recruiting
Testing a live tumor test for immune therapy response
This trial uses a special test on live tumor samples to see if it can predict how well immune checkpoint inhibitors (a type of immunotherapy) will work for different cancers. It may help doctors choose the best treatment for you.
Phoenix, ArizonaAges 18 years+ - NCT06563986RecruitingPhase 2
Combination therapy for advanced colorectal cancer in the liver
This trial tests a combination of two chemotherapy drugs (FTD and tipiracil), a targeted therapy (bevacizumab), and a radiation treatment (radioembolization) for people with colorectal cancer that has spread mainly to the liver and hasn't responded to other treatments. The goal is to see if this combination can shrink tumors and help control the cancer.
UtrechtAges 18 years+ - NCT06979908RecruitingPhase 2
A study of fruquintinib plus immunotherapy for advanced colorectal cancer
This trial tests a combination of three drugs (fruquintinib, a PD-1 inhibitor, and chidamide) for people with a specific type of advanced colorectal cancer that has not responded to at least two prior treatments. The goal is to see if this new combination can shrink tumors or slow the cancer's growth.
Changchun, JilinAges 18–75 - NCT07042685RecruitingPhase 2
5-FU and Fruquintinib for advanced colorectal cancer
This trial tests a combination of two drugs (5-FU and fruquintinib) in people with advanced colorectal cancer that cannot be removed by surgery or has spread. It is for those who have not had chemotherapy before.
Houston, TexasAges 18 years+ - NCT07371832Recruiting
AI Stapler vs. Standard Stapler for Colorectal Cancer Surgery
This trial compares a new AI-assisted robotic stapler to a standard stapler used during surgery for colorectal cancer that has not spread. The goal is to see if the new stapler is safer and works better.
Hyderabad, TelanganaAges 18–80 - NCT02732860Recruiting
Test your tumor’s drug response using a lab model
This trial grows a lab model from your own tumor tissue (or resected tissue) to predict which drugs might work best. It’s meant to match investigational treatments to your specific tumor biology.
Toronto, OntarioAges 18 years+ - NCT07504523RecruitingPhase 1
Personalized T-cell therapy for advanced colorectal cancer
This trial tests a custom-made T-cell treatment designed to target unique markers on your tumor. It's for people with advanced colorectal cancer who have run out of standard options or can't take them, and it aims to shrink tumors and improve survival.
Hangzhou, ZhejiangAges 18–70 - NCT06090994RecruitingPhase 4
Huaier vs capecitabine to prevent colon cancer return
This study compares two medicines to prevent colorectal cancer from coming back after surgery: a traditional Chinese medicine called Huaier and a standard chemotherapy pill called capecitabine. It is for people with stage 2 colon cancer that was completely removed.
Harbin, HeilongjiangAges 18 years+ - NCT04899908RecruitingPhase 2
Brain radiation with or without gadolinium nanoparticles for brain metastases
This trial tests whether adding tiny gadolinium-containing nanoparticles to standard brain radiation can better control brain metastases from certain cancers. It is for people with tumors that have grown after immunotherapy, are from certain cancers (like melanoma, GI, or HER2+ breast), are cystic, are large, or have come back after prior radiation.
Boston, MassachusettsAges 18 years+ - NCT06181344Recruiting
Helping with fear of cancer returning after treatment
This program helps people who have finished treatment for breast, gynecological, or colorectal cancer manage fears about their cancer coming back. It offers screening and support to address those worries.
Hong KongAges 18 years+ - NCT06307249RecruitingPhase 1
Precision therapy for solid tumors targeting CDK4/6 and VEGF
This trial tests a combination of two targeted drugs for advanced solid tumors like colorectal, lung, breast, and genitourinary cancers. The goal is to see if blocking certain proteins and a long RNA molecule can slow tumor growth.
Tripoli, North LebanonAges 18 years+ - NCT07227636RecruitingPhase 2
Immunotherapy for ctDNA-positive colorectal cancer after surgery
This trial tests two immunotherapy drugs, botensilimab and balstilimab, for people with colorectal cancer who have had surgery and chemotherapy but still have detectable cancer DNA in their blood. The goal is to see if these drugs can help clear the remaining cancer cells.
Basking Ridge, New JerseyAges 18 years+ - NCT06063018RecruitingPhase 2
Testing RC48 and Tislelizumab for recurrent cervical cancer with HER2
This trial tests a combination of two drugs, RC48 and Tislelizumab, for people with recurrent cervical cancer whose tumors have a protein called HER2. The goal is to see if this treatment can help when previous therapy has stopped working.
Beijing, Beijing MunicipalityAges 18–75 - NCT07696793RecruitingPhase 4
Simethicone colonoscopy prep for cancer screening
This trial tests a colonoscopy preparation drink that contains simethicone (a gas-relief ingredient) to see if it works better than standard prep for people who are already scheduled for a screening colonoscopy after a positive stool test. It may help make the procedure more comfortable and effective.
Barcelona, BarcelonaAges 50–69 - NCT07558083RecruitingPhase 3
Tracking colorectal cancer response using blood tests
This study tests whether a simple blood test can track how well your colorectal cancer is responding to first-line chemotherapy. By monitoring cancer markers in your blood, doctors may be able to detect treatment changes earlier than traditional imaging.
Mechelen, AntwerpenAges 18 years+
Hear when a new Colorectal Cancer Recurrent trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for colorectal cancer recurrent?
- Yes. Clin2 currently lists 230 recruiting colorectal cancer recurrent studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a colorectal cancer recurrent trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a colorectal cancer recurrent trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.